Abstract
Implementation of highly active antiretroviral therapy (HAART) has deeply changed the landscape of HIV-associated malignancies. Some AIDS-defining tumors, namely Primitive Lymphoma of Central Nervous System, have drastically declined, whereas a steady increase has been observed for non-AIDS-defining tumors, maybe due to longer survival of HIV-infected people. Easier immune restoration, subsequent to availability of a number of drugs targeting HIV at different points, has decreased opportunistic infections which hampered treatment of HIV-associated cancers. As a matter of fact these patients have been assimilated more and more with their negative counterpart, undergoing the same aggressive approach. Consistently, procedures that have been so far precluded to HIV + subjects, such as transplant of hemopoietic stem cells, either autologous or allogenic, and liver transplant are expected to be performed more and more extensively in this population. Which also would mean a full removal of the stigma which has weighed on it. Hence, it is true-like that malignancies and related problems may in the next future make up a main concern for the HIV specialist. Old and new challenges might be the drug-drug interaction of antiretrovirals or biotherapy-related infections or the debated question of an earlier HAART implementation in the course of HIV disease, with CD4 + cells >500/μl. In fact, if assimilation of HIV patients with cancer and the general population is a remarkable achieved goal, uniqueness of HIV infection in terms of immune status still makes HIV-associated cancer a unique chapter in the setting of Oncology.
| Original language | English |
|---|---|
| Pages (from-to) | 123-132 |
| Number of pages | 10 |
| Journal | Current HIV Research |
| Volume | 10 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Mar 2012 |
Fingerprint
Keywords
- Biotherapy
- Chemotherapy
- Highly active antiretroviral therapy
- Human immunodeficiency virus
- Malignancies
- Stem cell rescue
ASJC Scopus subject areas
- Infectious Diseases
- Virology
Cite this
Human immunodeficiency virus-associated malignancies : A therapeutic update. / Malfitano, Antonello; Barbaro, Giuseppe; Perretti, Alessandro; Barbarini, Giorgio.
In: Current HIV Research, Vol. 10, No. 2, 03.2012, p. 123-132.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Human immunodeficiency virus-associated malignancies
T2 - A therapeutic update
AU - Malfitano, Antonello
AU - Barbaro, Giuseppe
AU - Perretti, Alessandro
AU - Barbarini, Giorgio
PY - 2012/3
Y1 - 2012/3
N2 - Implementation of highly active antiretroviral therapy (HAART) has deeply changed the landscape of HIV-associated malignancies. Some AIDS-defining tumors, namely Primitive Lymphoma of Central Nervous System, have drastically declined, whereas a steady increase has been observed for non-AIDS-defining tumors, maybe due to longer survival of HIV-infected people. Easier immune restoration, subsequent to availability of a number of drugs targeting HIV at different points, has decreased opportunistic infections which hampered treatment of HIV-associated cancers. As a matter of fact these patients have been assimilated more and more with their negative counterpart, undergoing the same aggressive approach. Consistently, procedures that have been so far precluded to HIV + subjects, such as transplant of hemopoietic stem cells, either autologous or allogenic, and liver transplant are expected to be performed more and more extensively in this population. Which also would mean a full removal of the stigma which has weighed on it. Hence, it is true-like that malignancies and related problems may in the next future make up a main concern for the HIV specialist. Old and new challenges might be the drug-drug interaction of antiretrovirals or biotherapy-related infections or the debated question of an earlier HAART implementation in the course of HIV disease, with CD4 + cells >500/μl. In fact, if assimilation of HIV patients with cancer and the general population is a remarkable achieved goal, uniqueness of HIV infection in terms of immune status still makes HIV-associated cancer a unique chapter in the setting of Oncology.
AB - Implementation of highly active antiretroviral therapy (HAART) has deeply changed the landscape of HIV-associated malignancies. Some AIDS-defining tumors, namely Primitive Lymphoma of Central Nervous System, have drastically declined, whereas a steady increase has been observed for non-AIDS-defining tumors, maybe due to longer survival of HIV-infected people. Easier immune restoration, subsequent to availability of a number of drugs targeting HIV at different points, has decreased opportunistic infections which hampered treatment of HIV-associated cancers. As a matter of fact these patients have been assimilated more and more with their negative counterpart, undergoing the same aggressive approach. Consistently, procedures that have been so far precluded to HIV + subjects, such as transplant of hemopoietic stem cells, either autologous or allogenic, and liver transplant are expected to be performed more and more extensively in this population. Which also would mean a full removal of the stigma which has weighed on it. Hence, it is true-like that malignancies and related problems may in the next future make up a main concern for the HIV specialist. Old and new challenges might be the drug-drug interaction of antiretrovirals or biotherapy-related infections or the debated question of an earlier HAART implementation in the course of HIV disease, with CD4 + cells >500/μl. In fact, if assimilation of HIV patients with cancer and the general population is a remarkable achieved goal, uniqueness of HIV infection in terms of immune status still makes HIV-associated cancer a unique chapter in the setting of Oncology.
KW - Biotherapy
KW - Chemotherapy
KW - Highly active antiretroviral therapy
KW - Human immunodeficiency virus
KW - Malignancies
KW - Stem cell rescue
UR - http://www.scopus.com/inward/record.url?scp=84860308004&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84860308004&partnerID=8YFLogxK
U2 - 10.2174/157016212799937227
DO - 10.2174/157016212799937227
M3 - Article
C2 - 22329518
AN - SCOPUS:84860308004
VL - 10
SP - 123
EP - 132
JO - Current HIV Research
JF - Current HIV Research
SN - 1570-162X
IS - 2
ER -